Differences in Reported Anaphylaxis Associated with Common Nonsteroidal Anti-Inflammatory Drugs: A Pharmacovigilance Study.

IF 2.3 4区 医学 Q3 ALLERGY
Suwei Liu, Haoyang Yu, Yuxin Wu, Haogeng Wang, Yuxia Ma
{"title":"Differences in Reported Anaphylaxis Associated with Common Nonsteroidal Anti-Inflammatory Drugs: A Pharmacovigilance Study.","authors":"Suwei Liu, Haoyang Yu, Yuxin Wu, Haogeng Wang, Yuxia Ma","doi":"10.1159/000552828","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Nonsteroidal anti-inflammatory drugs (NSAIDs) are a major cause of drug hypersensitivity reactions, yet comparative real-world data on drug-specific anaphylaxis reporting remain limited. This study aimed to evaluate reporting patterns and disproportionality signals of NSAID-associated anaphylaxis in the FDA Adverse Event Reporting System (FAERS), compare severe outcomes across individual NSAIDs, and describe the indication context of these reports.</p><p><strong>Methods: </strong>In this cross-sectional pharmacovigilance study, FAERS reports from 2015Q1 to 2025Q2 were analyzed. Five NSAIDs were included: ibuprofen, diclofenac, naproxen, celecoxib, and meloxicam. Anaphylaxis was defined by 4 MedDRA preferred terms and restricted to reports listing the target NSAID as the primary suspect drug. Disproportionality was assessed using reporting odds ratio, proportional reporting ratio, empirical Bayes geometric mean, and information component.</p><p><strong>Results: </strong>Total adverse event reports were 51,837 for ibuprofen, 43,979 for diclofenac, 27,043 for naproxen, 13,085 for celecoxib, and 2,591 for meloxicam. Corresponding anaphylaxis reports were 938 (1.81%), 919 (2.09%), 320 (1.18%), 178 (1.36%), and 38 (1.47%). All 5 NSAIDs showed disproportionality signals versus all other drugs. Female predominance was observed across agents. Most reports involved adults aged 18-64 years, except meloxicam, which was concentrated in those aged 65-85 years. Diclofenac reports mainly originated outside the USA, whereas naproxen had the highest proportion of US reports. Among submitted FAERS reports of NSAID-associated anaphylaxis, the reported proportion of DE/LT outcomes varied across the 5 NSAIDs. Pain and back pain were common indications, but the broader indication patterns showed drug-specific features.</p><p><strong>Conclusion: </strong>NSAIDs showed consistent disproportionality signals for anaphylaxis in FAERS, with observable heterogeneity in reporting patterns across individual agents.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-10"},"PeriodicalIF":2.3000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Archives of Allergy and Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000552828","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs) are a major cause of drug hypersensitivity reactions, yet comparative real-world data on drug-specific anaphylaxis reporting remain limited. This study aimed to evaluate reporting patterns and disproportionality signals of NSAID-associated anaphylaxis in the FDA Adverse Event Reporting System (FAERS), compare severe outcomes across individual NSAIDs, and describe the indication context of these reports.

Methods: In this cross-sectional pharmacovigilance study, FAERS reports from 2015Q1 to 2025Q2 were analyzed. Five NSAIDs were included: ibuprofen, diclofenac, naproxen, celecoxib, and meloxicam. Anaphylaxis was defined by 4 MedDRA preferred terms and restricted to reports listing the target NSAID as the primary suspect drug. Disproportionality was assessed using reporting odds ratio, proportional reporting ratio, empirical Bayes geometric mean, and information component.

Results: Total adverse event reports were 51,837 for ibuprofen, 43,979 for diclofenac, 27,043 for naproxen, 13,085 for celecoxib, and 2,591 for meloxicam. Corresponding anaphylaxis reports were 938 (1.81%), 919 (2.09%), 320 (1.18%), 178 (1.36%), and 38 (1.47%). All 5 NSAIDs showed disproportionality signals versus all other drugs. Female predominance was observed across agents. Most reports involved adults aged 18-64 years, except meloxicam, which was concentrated in those aged 65-85 years. Diclofenac reports mainly originated outside the USA, whereas naproxen had the highest proportion of US reports. Among submitted FAERS reports of NSAID-associated anaphylaxis, the reported proportion of DE/LT outcomes varied across the 5 NSAIDs. Pain and back pain were common indications, but the broader indication patterns showed drug-specific features.

Conclusion: NSAIDs showed consistent disproportionality signals for anaphylaxis in FAERS, with observable heterogeneity in reporting patterns across individual agents.

与常见非甾体抗炎药相关的过敏反应报告的差异:一项药物警戒研究。
背景:非甾体类抗炎药(NSAIDs)是药物过敏的主要原因,但关于药物特异性过敏反应报告的比较真实证据仍然有限。目的:描述FDA不良事件报告系统(FAERS)中与非甾体抗炎药相关的过敏反应的报告模式和不成比例信号,比较不同药物的严重后果,并描述这些报告的指征背景。方法:在本横断面药物警戒研究中,对2015年第一季度至2015年第二季度的FAERS报告进行分析。包括5种非甾体抗炎药:布洛芬、双氯芬酸、萘普生、塞来昔布和美洛昔康。过敏反应由4个MedDRA首选术语定义,并且仅限于将目标非甾体抗炎药列为主要可疑药物的报告。使用报告优势比、比例报告比、经验贝叶斯几何平均和信息成分来评估歧化。结果:布洛芬的不良事件报告总数为51,837例,双氯芬酸为43,979例,萘普生为27,043例,塞来昔布为13,085例,美洛昔康为2,591例。相应的过敏反应报告分别为938例(1.81%)、919例(2.09%)、320例(1.18%)、178例(1.36%)和38例(1.47%)。所有5种非甾体抗炎药与所有其他药物相比均显示歧化信号。在各药剂中均观察到女性优势。大多数报告涉及18-64岁的成年人,除了美洛昔康,主要集中在65-85岁的成年人。双氯芬酸报告主要来自美国以外,而萘普生在美国报告中所占比例最高。在提交的FAERS报告nsaid相关的过敏反应中,报告的DE/LT结果比例在五种nsaid中有所不同。疼痛和背痛是常见的适应症,但更广泛的适应症模式显示出药物特异性特征。结论:非甾体抗炎药在FAERS过敏反应中显示出一致的歧化信号,在不同药物的报告模式中存在可观察到的异质性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
3.60%
发文量
105
审稿时长
2 months
期刊介绍: ''International Archives of Allergy and Immunology'' provides a forum for basic and clinical research in modern molecular and cellular allergology and immunology. Appearing monthly, the journal publishes original work in the fields of allergy, immunopathology, immunogenetics, immunopharmacology, immunoendocrinology, tumor immunology, mucosal immunity, transplantation and immunology of infectious and connective tissue diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书